Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    15468186 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Prostate Cancer
Interventions: Drug: Rosiglitazone;   Other: Placebo

Indicates status has not been verified in more than two years